Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused o

BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the C

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, o

HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a

NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Dimensional Fund Advisors LP boosted its holdings in Zevra Therapeutics, Inc. (NASDAQ: ZVRA) by 259.

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

Citizens analyst Jason N. Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperf

Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% fr

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.25 per share, beating the Zacks Con

Enrolled four patients in the event-driven Phase 3 DiSCOVER trial of celiprolol for the treatment of

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.25 per share which beat the analy

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.14 per share which beat the analy

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the C

Zevra investors who relied on public statements about arimoclomol's approval status faced losses aft

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused o

Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and pr

Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cocrystal Pharma (NASDAQ: COCP - Get Free Re

Zevra Therapeutics investors saw shares fall after European regulators issued a negative opinion on

NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK--(BUSINESS WIRE)--On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approxima

LOS ANGELES--(BUSINESS WIRE)--Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights li

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy a

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers

Wall Street analysts changed outlook on top names. See all rating changes on Benzinga's analyst

BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the pr

Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular

The CHMP issues a negative opinion on Zevra Therapeutics' arimoclomol for Niemann-Pick disease t

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's p

Under European regulatory procedures, the Company plans to request a re-examination of the CHMP opin

HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) (Zevra, or the Company), a commercial-stage company focused o

Maxim Group analyst Jason McCarthy maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and rais

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises

BTIG analyst Kambiz Yazdi reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises the p

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy a

Citizens analyst Jason Butler maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Market Outperform

Cantor Fitzgerald analyst Kristen Kluska maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Overwe

MIPLYFFA patent submitted for Orange Book listing, with patent protection to 2041Separately filed pa

Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and raises

Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly earnings of $0.18 per share which beat the analy

Zevra Therapeutics Inc. shares are trading higher on Monday after it agreed to sell its SDX Portfoli